2023 World Conference on Lung Cancer (Posters)-EP01.01. Evaluation of Perioperative Nintedanib for Lung Cancer with Idiopathic Pulmonary Fibrosis

EP01.01. Evaluation of Perioperative Nintedanib for Lung Cancer with Idiopathic Pulmonary Fibrosis - PDF(Slides)

Pdf Summary

This study aimed to evaluate the use of nintedanib, an antifibrotic agent, in preventing postoperative acute exacerbation of idiopathic pulmonary fibrosis (IPAE) in patients with lung cancer. A retrospective analysis was conducted on 11 patients with concomitant IPF and lung cancer who received perioperative nintedanib treatment. The patients had a mean age of 75.9 years and the majority were male. The surgical procedures performed included bi-lobectomy, lobectomy, segmentectomy, and wedge resection. The pathology results showed various types of lung cancer, including adenocarcinoma, squamous cell carcinoma, and small cell carcinoma. The pT classification indicated that most patients had stage 2 lung cancer, while the pN classification showed a mix of stage 0, 1, and 2 lymph node involvement. No patients developed postoperative IPAE, but some experienced complications such as prolonged air leak and surgical site infection. There were no perioperative deaths within 30 days. The study concluded that while further research is needed to determine the effectiveness and safety of perioperative nintedanib treatment, this study is a promising step in investigating its potential for preventing IPAE in patients with lung cancer and IPF.

Asset Subtitle

Ryusuke Sumiya

Meta Tag

Speaker Ryusuke Sumiya

Topic Risk Factors, Risk Reduction & Tobacco Control

Keywords

nintedanib

antifibrotic agent

postoperative acute exacerbation

idiopathic pulmonary fibrosis

IPAE

lung cancer

retrospective analysis

perioperative nintedanib treatment

surgical procedures

pathology results